Viatris Stock Outlook: Is Wall Street Bullish or Bearish?

Viatris Inc. (VTRS) is a global healthcare company formed through the merger of Mylan and Upjohn (a division of Pfizer) in November 2020. Headquartered in Canonsburg, Pennsylvania, Viatris focuses on providing access to medicines, sustainable healthcare solutions, and improving the lives of patients worldwide. The company commands a market cap of $13.2 billion and operates across several key segments, including generic pharmaceuticals, over-the-counter (OTC) products, and branded medications.

Viatris has lagged behind the broader market considerably over the past year. VTRS stock has dropped 8.1% over the past 52 weeks, compared to the S&P 500 Index’s ($SPX) 21.8% gains. In 2025, VTRS is down 12.5%, trailing the SPX’s 2.7% rise on a YTD basis.